Form 4 for ANGO ANGIODYNAMICS INC
Accepted 2026-07-24 18:10:51 ET · period of report 2026-07-22 · accession 0001140361-26-029633 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-24 18:10 | 2026-07-22 | ANGO | Clemmer James C | Pres, CEO, Dir | M - OptEx | $0.00 | +52.4K | 889.2K | +6% | $0 |
| D | 2026-07-24 18:10 | 2026-07-22 | ANGO | Clemmer James C | Pres, CEO, Dir | F - Tax | $13.82 | -26.7K | 862.4K | -3% | -$369.4K |
| D | 2026-07-24 18:10 | 2026-07-22 | ANGO | Clemmer James C | Pres, CEO, Dir | M - OptEx | $0.00 | -184.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-22 | M | A | 52,358 | $0.00 | 889,176 | D | — | — | (F1) This acquisition of 52,358 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023. |
| 2 | Common | Common Stock | 2026-07-22 | F | D | 26,728 | $13.82 | 862,448 | D | — | — | (F2) The exempt disposition of 26,728 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023. |
| 3 | Derivative | Performance Right | 2026-07-22 | M | D | 184,361 | $0.00 | 0 | D | — · — to — | 184,361 Common Stock | (F3) On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. (F3) On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. (F3) On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. |